By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

BioAxone Therapeutic Inc. 

Université de Montreal

Montreal      Canada
Phone: 514-990-1074 Fax:


SEARCH JOBS



Segment
Start Up





Company News
ALSERES Pharmaceuticals, Inc. (ALSE) and BioAxone Therapeutic Inc. Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology 4/30/2009 10:46:19 AM
BioAxone Therapeutic Inc. Licenses Phase II Spinal Cord Injury Drug Cethrin(R) To Boston Life Sciences (BLSI) 1/4/2007 11:58:50 AM
BioAxone Therapeutic Inc. Study Demonstrates Positive Interim Results For Spinal Cord Injury 11/27/2006 10:06:57 AM
BioAxone Therapeutic Inc. Announces Patients Completed The 6 Week Follow-Up In The Phase I/IIa Trial Of Cethrin(R) For The Treatment Of Acute Spinal Cord Injury 9/19/2006 2:20:20 PM
BioAxone Therapeutic Inc. Completes Patient Enrollment For Phase I/IIa Trial Of Cethrin(R) In Treatment Of Acute Spinal Cord Injury 7/10/2006 10:35:51 AM
BioAxone Therapeutic Inc. Announces Closing Of $5.1 Million 12/19/2005 10:26:22 AM
BioAxone Therapeutic Inc. Release: Cethrin(R) Receives Orphan Drug Status 12/12/2005 12:09:25 PM
BioAxone Therapeutic Inc. Appoints Patrick Tremblay Vice President Research & Development 11/29/2005 10:44:39 AM
BioAxone Therapeutic Inc. Announces First Patient Treatment In Acute Spinal Cord Injury Trial10/19/2005 5:12:38 PM
BioAxone Therapeutic Inc. Announces A Second-Round Investment Of $12.15 Million10/19/2005 5:09:54 PM
//-->